Logo image of SER

SERINA THERAPEUTICS INC. (SER) Stock Fundamental Analysis

USA - NYSEARCA:SER - US81751A1088 - Common Stock

5.58 USD
-0.05 (-0.89%)
Last: 10/9/2025, 9:40:28 PM
5.4 USD
-0.18 (-3.23%)
After Hours: 10/9/2025, 9:40:28 PM
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to SER. SER was compared to 536 industry peers in the Biotechnology industry. While SER seems to be doing ok healthwise, there are quite some concerns on its profitability. SER has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year SER has reported negative net income.
In the past year SER has reported a negative cash flow from operations.
SER had negative earnings in each of the past 5 years.
In the past 5 years SER always reported negative operating cash flow.
SER Yearly Net Income VS EBIT VS OCF VS FCFSER Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M

1.2 Ratios

SER has a worse Return On Assets (-124.61%) than 81.16% of its industry peers.
SER's Return On Equity of -618.26% is on the low side compared to the rest of the industry. SER is outperformed by 79.48% of its industry peers.
Industry RankSector Rank
ROA -124.61%
ROE -618.26%
ROIC N/A
ROA(3y)-204.08%
ROA(5y)-232.88%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
SER Yearly ROA, ROE, ROICSER Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 -500 -1K -1.5K

1.3 Margins

SER does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SER Yearly Profit, Operating, Gross MarginsSER Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10K -20K -30K

More info and screens

6

2. Health

2.1 Basic Checks

SER does not have a ROIC to compare to the WACC, probably because it is not profitable.
SER has more shares outstanding than it did 1 year ago.
The number of shares outstanding for SER has been reduced compared to 5 years ago.
There is no outstanding debt for SER. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
SER Yearly Shares OutstandingSER Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
SER Yearly Total Debt VS Total AssetsSER Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M

2.2 Solvency

SER has an Altman-Z score of -9.45. This is a bad value and indicates that SER is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of SER (-9.45) is worse than 72.01% of its industry peers.
There is no outstanding debt for SER. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -9.45
ROIC/WACCN/A
WACC9.51%
SER Yearly LT Debt VS Equity VS FCFSER Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M -20M

2.3 Liquidity

SER has a Current Ratio of 2.24. This indicates that SER is financially healthy and has no problem in meeting its short term obligations.
SER has a Current ratio of 2.24. This is in the lower half of the industry: SER underperforms 72.20% of its industry peers.
SER has a Quick Ratio of 2.24. This indicates that SER is financially healthy and has no problem in meeting its short term obligations.
With a Quick ratio value of 2.24, SER is not doing good in the industry: 69.96% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 2.24
Quick Ratio 2.24
SER Yearly Current Assets VS Current LiabilitesSER Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 88.97% over the past year.
Looking at the last year, SER shows a very negative growth in Revenue. The Revenue has decreased by -60.56% in the last year.
Measured over the past years, SER shows a very negative growth in Revenue. The Revenue has been decreasing by -49.65% on average per year.
EPS 1Y (TTM)88.97%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-205.45%
Revenue 1Y (TTM)-60.56%
Revenue growth 3Y-26.32%
Revenue growth 5Y-49.65%
Sales Q2Q%154.9%

3.2 Future

The Earnings Per Share is expected to grow by 4.65% on average over the next years.
Based on estimates for the next years, SER will show a very negative growth in Revenue. The Revenue will decrease by -25.99% on average per year.
EPS Next Y-42.1%
EPS Next 2Y-8.67%
EPS Next 3Y4.65%
EPS Next 5YN/A
Revenue Next Year134.46%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
SER Yearly Revenue VS EstimatesSER Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500K 1M 1.5M
SER Yearly EPS VS EstimatesSER Yearly EPS VS EstimatesYearly EPS VS Estimates 2025 2026 2027 -0.5 -1 -1.5 -2

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for SER. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SER. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SER Price Earnings VS Forward Price EarningsSER Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SER Per share dataSER EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1 -1.5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-8.67%
EPS Next 3Y4.65%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for SER!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SERINA THERAPEUTICS INC.

NYSEARCA:SER (10/9/2025, 9:40:28 PM)

After market: 5.4 -0.18 (-3.23%)

5.58

-0.05 (-0.89%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-11 2025-08-11/amc
Earnings (Next)11-10 2025-11-10
Inst Owners4.05%
Inst Owner Change0%
Ins Owners18.23%
Ins Owner Change0%
Market Cap58.81M
Analysts80
Price Target13.26 (137.63%)
Short Float %2.11%
Short Ratio0.55
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-16%
Min EPS beat(2)-53.76%
Max EPS beat(2)21.75%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)18.18%
EPS NQ rev (1m)-17.78%
EPS NQ rev (3m)-23.26%
EPS NY rev (1m)-23.48%
EPS NY rev (3m)-9.23%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1050.24
P/FCF N/A
P/OCF N/A
P/B 32.64
P/tB 32.64
EV/EBITDA N/A
EPS(TTM)-1.51
EYN/A
EPS(NY)-1.79
Fwd EYN/A
FCF(TTM)-1.49
FCFYN/A
OCF(TTM)-1.48
OCFYN/A
SpS0.01
BVpS0.17
TBVpS0.17
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -124.61%
ROE -618.26%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-204.08%
ROA(5y)-232.88%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 37.24%
Cap/Sales 96.43%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.24
Quick Ratio 2.24
Altman-Z -9.45
F-Score3
WACC9.51%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)88.97%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-205.45%
EPS Next Y-42.1%
EPS Next 2Y-8.67%
EPS Next 3Y4.65%
EPS Next 5YN/A
Revenue 1Y (TTM)-60.56%
Revenue growth 3Y-26.32%
Revenue growth 5Y-49.65%
Sales Q2Q%154.9%
Revenue Next Year134.46%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5YN/A
EBIT growth 1Y-71.16%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-143.43%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-142.59%
OCF growth 3YN/A
OCF growth 5YN/A